The leukocyte Fcγ receptor (FcγR)-mediated response is important for the efficacy of
therapeutic antibodies; however, little is known about the role of FcγRs in other cell types …

Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in
durable patient benefit. However, response rates in breast cancer patients remain modest …

Combining immunogenic cell death-inducing chemotherapies and PD-1 blockade can
generate remarkable tumor responses. It is now well established that TGF-β1 signaling is a …

Enhancing natural killer (NK) cell–based cancer immunotherapy by overcoming
immunosuppression is an area of intensive research. Here, we have demonstrated that the …

Abstract Vγ9Vδ2 T cells exert potent cytotoxicity toward various tumor cells and adoptive
transfer of Vγ9Vδ2 T cells is an attractive proposition for cell based immunotherapy. Vγ9Vδ2 …

Trastuzumab has been used for the treatment of HER2-overexpressing breast cancer for
more than a decade, but the mechanisms of action for the therapy are still being actively …

About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do
not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment …

Aberrant skipping of coding exons in CD19 and CD22 compromises the response to
immunotherapy in B-cell malignancies. Here, we showed that the MS4A1 gene encoding …

Recent studies suggest that tumor-associated CD11b+ Gr1+ myeloid cells contribute to
refractoriness to antiangiogenic therapy with an anti-VEGF-A antibody. However, the …

Resistance to the anti-HER2 monoclonal antibody trastuzumab is a major problem in the
treatment of HER2-overexpressing metastatic breast cancer. Growth differentiation factor 15 …